Category: Parkinsonism, Others
Objective: Data from the PRISM study on patient characteristics, treatment patterns and burden of disease in people with Parkinson’s disease (PwP) are presented.
Background: PRISM was a European survey of the burden of Parkinson’s disease (PD), medication use, healthcare resource utilisation and health-related quality of life (HRQoL) PwP and their care-partners.
Method: PRISM was a descriptive, exploratory, observational study with cross-sectional design. The survey was designed in collaboration with The Cure Parkinson’s Trust (a UK-based advocacy group) and an international scientific committee. Data was collected using an online survey completed by PwP and their care-partners as matched samples. Multivariate analysis was used to explore drivers of Parkinson’s Disease Questionnaire-39 (PDQ-39) summary score.
Results: Between April-July 2019, data was collected from 861 PwP (599 complete responses; 262 partial responses) from six European countries (characteristics in Table 1). Levodopa was used by 84% of PwP in the previous 12 months and as monotherapy in 22% of all PwP (Table 2). In 67% of PwP (544/812), levodopa was the first prescribed anti-PD medication. PwP had impaired HRQoL (mean±standard deviation PDQ-39 score, 32.1±18.3), a wide range of non-motor symptoms (mean±standard deviation Non-Motor Symptoms Questionnaire score, 12.8±6.0) and frequent issues with sexual functioning (Table 3). Higher numbers of comorbidities and non-motor symptoms were associated with worse HRQoL (Table 3).
Conclusion: Two-thirds of PRISM respondents have been levodopa users since PD treatment start, in contrast to previous prescription patterns , and experienced decreased HRQoL in relation to more comorbidities and non-motor symptoms.
References: 1. Fargel et al. Clin Drug Invest 2007;27(3):207-218.
To cite this abstract in AMA style:T. Foltynie, E. Tolosa, J. Ferreira, A. Antonini, A. Lees, G. Ebersbach, O. Rascol, J.F Rocha, D. Magalhães, P. Soares-da-Silva. Patient Characteristics, Treatment Patterns and Disease Burden in People with Parkinson’s Disease: Insights from the Parkinson’s Disease Real-World Impact Assessment (PRISM) Study [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/patient-characteristics-treatment-patterns-and-disease-burden-in-people-with-parkinsons-disease-insights-from-the-parkinsons-disease-real-world-impact-assessment-prism-study/. Accessed December 5, 2023.
« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/patient-characteristics-treatment-patterns-and-disease-burden-in-people-with-parkinsons-disease-insights-from-the-parkinsons-disease-real-world-impact-assessment-prism-study/